Literature DB >> 25371147

Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study.

Gad Cotter1, Marco Metra, Beth A Davison, Stefanie Senger, Robert C Bourge, John G F Cleland, Guillaume Jondeau, Henry Krum, Christopher M O'Connor, John D Parker, Guillermo Torre-Amione, Dirk J van Veldhuisen, Olga Milo, Isaac Kobrin, Maurizio Rainisio, John J V McMurray, John R Teerlink.   

Abstract

AIMS: Worsening heart failure (WHF) in the first 7 days after an admission for acute HF (AHF) has been proposed as a therapeutic target in several recent AHF studies and was a co-primary endpoint of the VERITAS studies. METHODS AND
RESULTS: Patients were randomized within 24 h of admission for AHF. WHF was defined as worsening or persistent signs and symptoms of HF requiring additional intravenous or mechanical therapy for HF or death within 7 days of randomization. Multivariable models were developed to predict the time to WHF through day 7. Unadjusted and multivariable-adjusted associations of WHF with the length of stay (LOS) of the index hospitalization, and 30- and 90-day outcomes were estimated. WHF occurred by day 7 in 27% of the 1347 patients enrolled. Age, co-morbidities, and markers of HF severity were moderately predictive of WHF; the C-index for a multivariable model for WHF was 0.66. After multivariable adjustment for baseline characteristics, WHF was associated with an increase in LOS of 4.33 days [95% confidence interval (CI) 3.54-5.13 days], a hazard ratio (HR) for 30-day HF readmission or death of 2.43 (95% CI 1.75-3.40), and a HR for 90-day mortality of 2.57 (95% CI 1.81-3.65), all with P < 0.0001.The associations of WHF with these outcomes remained largely unchanged after adjustment for both baseline characteristics and changes in markers of renal and hepatic dysfunction during the first day of admission.
CONCLUSIONS: In patients admitted for AHF, WHF is a significant clinical event that is associated with delays in discharge and higher rates for readmission and death.
© 2014 The Authors European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  Acute heart failure; Death; Outcome; VERITAS study; Worsening heart failure

Mesh:

Substances:

Year:  2014        PMID: 25371147     DOI: 10.1002/ejhf.186

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  10 in total

Review 1.  The Impact of Worsening Heart Failure in the United States.

Authors:  Lauren B Cooper; Adam D DeVore; G Michael Felker
Journal:  Heart Fail Clin       Date:  2015-08-11       Impact factor: 3.179

2.  Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial.

Authors:  Robert J Mentz; Marco Metra; Gad Cotter; Olga Milo; Colleen McKendry; Karen Chiswell; Beth A Davison; John G F Cleland; Daniel M Bloomfield; Howard C Dittrich; Mona Fiuzat; Piotr Ponikowski; Michael M Givertz; Adriaan A Voors; John R Teerlink; Christopher M O'Connor
Journal:  Eur J Heart Fail       Date:  2015-06-17       Impact factor: 15.534

3.  Differences in health care use and outcomes by the timing of in-hospital worsening heart failure.

Authors:  Lauren B Cooper; Bradley G Hammill; Puza P Sharma; Adam D DeVore; Robert J Mentz; Gregg C Fonarow; Peter S Pang; Lesley H Curtis; Adrian F Hernandez
Journal:  Am Heart J       Date:  2015-09-11       Impact factor: 4.749

Review 4.  Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.

Authors:  Pablo Garcia-Pavia; Frank Bengel; Dulce Brito; Thibaud Damy; Franz Duca; Sharmila Dorbala; Jose Nativi-Nicolau; Laura Obici; Claudio Rapezzi; Yoshiki Sekijima; Perry M Elliott
Journal:  Eur J Heart Fail       Date:  2021-05-24       Impact factor: 17.349

5.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

Review 6.  What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?

Authors:  Jane A Cannon; Andrew R McKean; Pardeep S Jhund; John J V McMurray
Journal:  Open Heart       Date:  2015-12-23

7.  Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.

Authors:  John R Teerlink; Adriaan A Voors; Piotr Ponikowski; Peter S Pang; Barry H Greenberg; Gerasimos Filippatos; G Michael Felker; Beth A Davison; Gad Cotter; Claudio Gimpelewicz; Leandro Boer-Martins; Margaret Wernsing; Tsushung A Hua; Thomas Severin; Marco Metra
Journal:  Eur J Heart Fail       Date:  2017-04-28       Impact factor: 15.534

8.  Optimal hydration volume among high-risk patients with advanced congestive heart failure undergoing coronary angiography.

Authors:  Shi-Qun Chen; Yong Liu; Wei Jie Bei; Ying Wang; Chong-Yang Duan; Deng-Xuan Wu; Kun Wang; Ping Yan Chen; Ji-Yan Chen; Ning Tan; Li-Wen Li
Journal:  Oncotarget       Date:  2018-05-04

Review 9.  In-hospital worsening heart failure: a clinically relevant endpoint?

Authors:  Andrew L Clark; Myriam Cherif; Theresa A McDonagh; Iain B Squire
Journal:  ESC Heart Fail       Date:  2017-07-18

10.  The impact of clinical and angiographic factors on percutaneous coronary angioplasty outcomes in patients with acute ST-elevation myocardial infarction.

Authors:  Mindaugas Barauskas; Ramunas Unikas; Egle Tamulenaite; Ruta Unikaite
Journal:  Arch Med Sci Atheroscler Dis       Date:  2016-12-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.